Sage Therapeutics Announced the Launch of Postpartum Depression (PPD) Therapy Zulresso to Expand its Presence Depression Therapeutics Market
The high prevalence and incidence rate of mental disorders such as anxiety, major depressive disorder, and associated co-morbidities are playing a significant role in the overall development of the D epression T herapeutics M arket . According to the World Health Organization, depression is a common mental disorder and one of the main causes of disability worldwide. Globally, an estimated 264 million people are affected by depression. More women are affected than men. Low costs of antidepressant therapies coupled with a lack of alternative therapies are also augmenting the growth of the market. Growing awareness regarding depression and various treatments among people are again supporting the growth of the depression therapeutics market. In March 2019, Sage Therapeutics announced the launch of postpartum depression (PPD) therapy Zulresso (brexanolone) to treat Central nervous system (CNS) disorder In January 2019, Otsuka America, Inc., and Click Therapeutics,...